Literature DB >> 19402201

Respiratory function as a marker of bone health and fracture risk in an older population.

Alireza Moayyeri1, Sheila A Bingham, Robert N Luben, Nicholas J Wareham, Kay-Tee Khaw.   

Abstract

Identification of those at high risk of osteoporosis and fractures using clinically available tests beyond BMD measures is a major clinical challenge. We examined forced expiratory volume in 1 s (FEV1), an easily obtainable measure of respiratory function, as a clinical measure for fracture prediction. In the context of the European Prospective Investigation into Cancer-Norfolk Study, 8304 women and 6496 men 42-81 yr of age underwent a health check including spirometry and heel quantitative ultrasonography between 1997 and 2000 and were followed up for incident hip fractures until 2007. The main outcome measures were broadband ultrasound attenuation (BUA) of the heel (cross-sectional analysis) and hip fracture risk (prospective analysis). In multivariate regression models, a 1-liter increase in FEV1 was associated with a statistically significant 2.2-dB/MHz increase in BUA, independent of age, smoking, height, body mass index, history of fracture, and use of corticosteroids. Mean FEV1 was significantly lower among 84 women and 36 men with hip fracture compared with other participants. In multivariate proportional-hazard regression models, the relative risk (RR) of hip fracture associated with a 1-liter increase in FEV1 was 0.5 (95% CI, 0.3-0.9; p < 0.001) for both men and women. RR of hip fracture for a 1 SD increase in FEV1 was approximately equivalent to a 0.5 SD increase in BUA among women (1 SD among men) and an 5-yr decrease in age among both men and women. Middle-aged and older people with low respiratory function are at increased risk of osteoporosis and hip fracture. FEV1, an easy, low-cost, and feasible clinical measure, may help improve the identification of high-risk groups.

Entities:  

Mesh:

Year:  2009        PMID: 19402201     DOI: 10.1359/jbmr.081231

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  7 in total

1.  Amount of smoking, pulmonary function, and bone mineral density in middle-aged Korean men: KNHANES 2008-2011.

Authors:  Ji Hyun Lee; A Ram Hong; Jung Hee Kim; Kyoung Min Kim; Bo Kyung Koo; Chan Soo Shin; Sang Wan Kim
Journal:  J Bone Miner Metab       Date:  2017-01-31       Impact factor: 2.626

2.  Relationship between femur neck bone mineral density and prevalent chronic obstructive pulmonary disease (COPD) or COPD mortality in older non-Hispanic white adults from NHANES III.

Authors:  A C Looker
Journal:  Osteoporos Int       Date:  2014-01-17       Impact factor: 4.507

3.  Airflow limitation as a risk factor for low bone mineral density and hip fracture.

Authors:  Trine Herland; Ellen M Apalset; Geir Egil Eide; Grethe S Tell; Sverre Lehmann
Journal:  Eur Clin Respir J       Date:  2016-10-11

4.  Association between airflow limitation severity and reduced bone mineral density in Japanese men.

Authors:  Kazuhiko Watanabe; Ayumi Onoue; Kenichi Kubota; Noritaka Higashi; Toshinari Hayashi; Tohru Tsuda; Hisamitsu Omori
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-10-16

5.  Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity.

Authors:  Joseph Finkelstein; Eunme Cha; Steven M Scharf
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-09-24

6.  The relationship between adipokines, body composition, and bone density in men with chronic obstructive pulmonary disease.

Authors:  Sheryl F Vondracek; Norbert F Voelkel; Michael T McDermott; Connie Valdez
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-07-20

7.  Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study.

Authors:  Pere Almagro; Pablo Martinez-Camblor; Joan B Soriano; Jose M Marin; Inmaculada Alfageme; Ciro Casanova; Cristobal Esteban; Juan J Soler-Cataluña; Juan P de-Torres; Bartolome R Celli; Marc Miravitlles
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.